🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Regulation of T cell immune response in Heart Failure with Preserved Ejection Fraction
Organization TUFTS UNIVERSITY BOSTONLocation BOSTON, UNITED STATESPosted 1 Apr 2023Deadline 31 Jul 2025 ⚠️
NIHUS FederalResearch GrantFY2025ATF-1ATF1ATF6ATF6 geneActivating Transcription Factor 6AffectAntibodiesAntigensBioavailabilityBiological AvailabilityCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCardiacCardiac Muscle CellsCardiac MyocytesCardiocyteCause of DeathCell BodyCell IsolationCell SegregationCell SeparationCell Separation TechnologyCellsCellular biologyClinicalComplexDataDependenceDevelopmentDiastolic heart failureDiseaseDisorderDown-RegulationDysfunctionEFRACER stressEjection FractionElementsEndogenous Nitrate VasodilatorEndothelium-Derived Nitric OxideEpidemiologic ResearchEpidemiologic StudiesEpidemiological StudiesEpidemiology ResearchEstersExperimental ModelsExpression SignatureFosteringFunctional disorderGene Expression ProfileGenesGoalsHF with preserved ejection fractionHFpEFHeartHeart Muscle CellsHeart Muscle tissueHeart failureHeart myocyteHigh Fat DietHospital AdmissionHospitalizationHumanHypertensionHypertrophyImmuneImmune responseImmunesImmunomodulationImpairmentInfiltrationInflammationInflammatoryL-NAMEMHC ReceptorMajor Histocompatibility Complex ReceptorMediatingMetabolic stressMetabolic syndromeMiceMice MammalsModelingModern ManMolecularMononitrogen MonoxideMurineMusMyocardialMyocardial tissueMyocardiumN omega-Nitro-L-ArginineN omega-Nitro-L-arginine Methyl EsterN(G)-Nitro-L-arginine Methyl EsterN(G)-NitroarginineN(G)-Nitroarginine Methyl EsterN(omega)-NitroarginineNG-Nitro-L-ArginineNG-Nitro-L-Arginine Methyl EsterNG-NitroarginineNG-Nitroarginine Methyl EsterNO2ArgNOARGNitric OxideNitroarginineNitrogen MonoxideNitrogen ProtoxideObesityOrganellesOutcomePathway interactionsPatientsPhenotypePhysiologic AvailabilityPhysiopathologyPre-Clinical ModelPreclinical ModelsProcessProteinsRNA SeqRNA sequencingRNAseqRelaxationResponse ElementsRodent ModelRoleStressSyndromeT cell infiltrationT cell regulationT cell responseT-Cell Antigen ReceptorsT-Cell ReceptorT-Cell SubsetsT-CellsT-LymphocyteT-Lymphocyte SubsetsT-cell inflamedT4 CellsT4 LymphocytesTeff cellTestingTranscriptTransgenic MiceTumor ImmunityVascular Hypertensive DiseaseVascular Hypertensive DisorderWild Type Mouseactivating transcription factor 1adiposityantagonismantagonistanti-canceranti-tumor immunityantitumor immunitybiological adaptation to stresscancer immunitycardiac failurecardiac musclecardiometaboliccardiometabolismcardiomyocytecell biologycell sortingco-morbidco-morbiditycomorbiditycopingcorpulencecytokinedevelopmentaleffector T cellendoplasmic reticulum stressendothelial cell derived relaxing factorepidemiologic investigationepidemiology studyfeedinggain of functiongene expression patterngene expression signatureheart failure and reduced ejection fractionheart failure with preserved ejection fractionheart failure with preserved systolic functionheart failure with reduced ejection fractionheart musclehigh blood pressurehost responsehyperpiesiahyperpiesishypertensive diseasehypertensive disorderimmune modulating strategyimmune modulationimmune modulatory strategyimmune regulationimmune system responseimmunogenimmunologic reactivity controlimmunomodulatoryimmunomodulatory strategyimmunoregulationimmunoregulatoryimmunoresponseimprovedinsightloss of functionmouse modelmurine modelnitrosative stressnovelomega-Nitroarginineoverexpressoverexpressionpathophysiologypathwaypreservationpreserved ejection fraction heart failureprogramsprotein foldingreaction; crisisresponsesensorsocial rolestress responsestress; reactionthymus derived lymphocytetranscriptional profiletranscriptional signaturetranscriptome sequencingtranscriptomic sequencingtumorvalsartanwildtype mouse
Applications closed.
Description preview
The goal of this R01 application is to investigate the mechanisms by which T cells contribute to heart failure
(HF) with preserved ejection fraction (HFpEF), affecting roughly 50% of the HF patients. Notably, the
treatments that improve survival and outcomes in patients with HF with reduced ejection fraction (HFrEF)
have not provided clinical…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click